Eureka Genomics announces closing of $3.7M private financing round

Eureka GenomicsMar 11 2010

Eureka Genomics today announced the closing of a $3.7 million private financing round whose participants included private individuals and undisclosed angel investors. The proceeds will further discovery research aimed at identifying novel microorganisms associated with specific cancers and other important diseases, as well as help grow Eureka Genomics’ high-throughput sequencing and bioinformatics service business on a global basis. Eureka Genomics is an industry leader in the area of advanced bioinformatics analysis associated with next-generation sequencing data, and a provider of high-end services to diagnostics, pharmaceutical/biotechnology, agricultural and cleantech companies, as well as academic, public and private research laboratories.

“This funding will support the advancement of our lead programs in colorectal cancer, lymphoma and cardiovascular disease”

“This funding will support the advancement of our lead programs in colorectal cancer, lymphoma and cardiovascular disease,” said Didier Perez, co-founder and Chief Operating Officer for Eureka Genomics. “Our advanced next-generation sequencing and bioinformatics capabilities have already resulted in the discovery of unique microbial associations with disease in animals and plants, and we are working to extend our discoveries to humans.”

He noted that since Eureka Genomics’ founding in 2007, the company has formed a growing number of partnerships and collaborations with leading academic, governmental and private research organizations. “We intend to continue adding new partners over the coming year, including corporate collaborators for the co-development and commercialization of vaccines and diagnostics based on our discoveries.”

Eureka Genomics also plans to use the funds to help grow global sales and marketing for its high-end sequencing and bioinformatics business. “Over the course of our discovery research we have developed advanced capabilities in high-throughput sequencing and bioinformatics analysis that we leverage and bring to bear on our customers’ everyday problems,” said Heather Koshinsky, Ph.D., Eureka Genomics’ co-founder and Chief Scientific Officer. “We have already gained widespread industry recognition as the leading provider of solutions to scientifically complex problems not addressable by other high-throughput sequencing and bioinformatics services. Our expertise and offerings ensure that Eureka Genomics’ customers can quickly get the information and answers they need on a cost effective basis.